Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138254 | 1.00 | TSHR (0.42) | TSHRNPSR1HTTALDH1A1GABRA5 | |
| SCHEMBL20137910 | 0.83 | TSHR (0.40) | TSHRNPSR1HTTALDH1A1MEN1 | |
| SCHEMBL20138284 | 0.80 | TSHR (0.39) | TSHRHTTALDH1A1GABRA5L3MBTL1 | |
| SCHEMBL20138136 | 0.77 | TSHR (0.41) | TSHRNPSR1HTTALDH1A1MEN1 | |
| SCHEMBL20137996 | 0.77 | TSHR (0.36) | TSHRNPSR1HTTALDH1A1MEN1 | |
| SCHEMBL20138234 | 0.77 | TSHR (0.39) | TSHRNPSR1HTTALDH1A1 | |
| SCHEMBL20138011 | 0.76 | TSHR (0.35) | TSHRNPSR1HTTALDH1A1MEN1 | |
| SCHEMBL20137982 | 0.76 | TSHR (0.35) | TSHRNPSR1HTTALDH1A1MEN1 | |
| SCHEMBL20138048 | 0.76 | TSHR (0.35) | TSHRNPSR1HTTALDH1A1MEN1 | |
| SCHEMBL20137997 | 0.75 | TSHR (0.37) | TSHRNPSR1HTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | TSHR 2169/4885NPSR1 1482/4885HTT 303/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | TSHR 940/4885NPSR1 427/4885HTT 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.